Other languages Azitra, Inc.

Equities

AZTR

US05479L1044

Real-time Estimate Cboe BZX Other stock markets 09:52:05 2024-05-20 am EDT			5-day change	1st Jan Change
0.185 ^USD	+1.65%		-1.28%	-79.83%

May. 10	Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	CI
May. 09	Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Azitra, Inc. Announces Positive Preclinical Data of ATR-12 and Clinical Design in Netherton Syndrome Presented at the ASGCT Annual Meeting	May. 10
Azitra, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Azitra, Inc. Announces New Preclinical Data to be Presented at the American Society of Gene and Cell Therapy Meeting	Apr. 22
Azitra, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15
Azitra Closes $5 Million Public Offering	Feb. 16
Top Midday Decliners	Feb. 14
Azitra Prices Stock Offering at $0.30 a Share	Feb. 14
Azitra Launches Common Stock Offering; Shares Drop	Jan. 19
Azitra, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023	Nov. 14
Azitra Adds Barbara Ryan and John Schroer to Its Board of Directors	23-07-19
Azitra, Inc. Appoints Travis Whitfill as Chief Operating Officer	23-07-10
Top Premarket Decliners	23-07-06
Insider Buy: Azitra	23-06-26
Insider Buy: Azitra	23-06-26
Azitra Closes IPO, Raises $7.5 Million Gross Proceeds	23-06-22
Azitra Shares Fall in NYSE American Debut	23-06-16
Azitra, Inc. has completed an IPO in the amount of $7.5 million.	23-06-15
Azitra Inc Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Azitra, Inc. has filed an IPO in the amount of $17.25 million.	23-02-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.

BENEFIT NOW